Zealand Pharma Announces Financial Results for the First Nine Months of 2023
09 nov. 2023 01h00 HE
|
Zealand Pharma
Company announcement - No. 38 / 2023 Zealand Pharma Announces Financial Results for the First Nine Months of 2023 Strong progress across obesity pipeline, first PDUFA date for...
Zealand Pharma to participate in the Jefferies London Healthcare Conference in November 2023
07 nov. 2023 04h00 HE
|
Zealand Pharma
Press release – No. 15 / 2023 Zealand Pharma to participate in the Jefferies London Healthcare Conference in November 2023 Copenhagen, Denmark, November 7, 2023 – Zealand Pharma A/S (Nasdaq: ZEAL)...
Zealand Pharma conference call on November 9 at 2pm CET (8am ET) to present third quarter 2023 results
03 nov. 2023 12h00 HE
|
Zealand Pharma
Press Release – No. 14 / 2023 Zealand Pharma conference call on November 9 at 2pm CET (8am ET) to present third quarter 2023 results Copenhagen, Denmark, November 3, 2023 – a Zealand...
Zealand Pharma major shareholder announcement: Polar Capital
20 oct. 2023 16h00 HE
|
Zealand Pharma
Company announcement – No. 37 / 2023 Zealand Pharma major shareholder announcement: Polar Capital Copenhagen, Denmark, 20 October 2023 – Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL) (CVR-no. 20...
Zealand Pharma presents data for amylin analog ZP8396 at ObesityWeek
17 oct. 2023 02h00 HE
|
Zealand Pharma
Press release – No. 13 / 2023 Zealand Pharma presents data for amylin analog ZP8396 at ObesityWeek Copenhagen, Denmark, October 17, 2023 – Zealand Pharma A/S (Nasdaq: ZEAL) (“Zealand”) (CVR-no....
Phase III studies to investigate survodutide for people living with obesity and overweight, with and without diabetes, cardiovascular disease and chronic kidney disease
05 oct. 2023 05h53 HE
|
Zealand Pharma
Phase III studies to investigate survodutide for people living with obesity and overweight, with and without diabetes, cardiovascular disease and chronic kidney disease Press release – No. 12 /...
Total number of shares and voting rights in Zealand Pharma at September 29, 2023
29 sept. 2023 11h15 HE
|
Zealand Pharma
Company announcement – No. 36 / 2023 Total number of shares and voting rights in Zealand Pharma at September 29, 2023 Copenhagen, Denmark, September 29, 2023 – Zealand Pharma A/S (“Zealand”)...
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
14 sept. 2023 16h30 HE
|
Zealand Pharma
Company announcement – No. 35 / 2023 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons ...
Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants
14 sept. 2023 16h00 HE
|
Zealand Pharma
Company announcement – No. 34 / 2023 Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants Copenhagen, Denmark, September 14, 2023 – Zealand Pharma A/S...
SAVE THE DATE: Zealand Pharma to host Obesity R&D Event in London on December 5, 2023
08 sept. 2023 05h00 HE
|
Zealand Pharma
Press release – No. 11 / 2023 SAVE THE DATE: Zealand Pharma to host Obesity R&D Event in London on December 5, 2023 Copenhagen, Denmark, September 8, 2023 – Zealand Pharma A/S (Nasdaq: ZEAL)...